

# Alfred Kim

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9131754/publications.pdf>

Version: 2024-02-01

72  
papers

4,099  
citations

186265  
28  
h-index

138484  
58  
g-index

78  
all docs

78  
docs citations

78  
times ranked

9118  
citing authors

#	ARTICLE	IF	CITATIONS
1	Depressed Symptomatology in Systemic Lupus Erythematosus Patients. <i>Arthritis Care and Research</i> , 2023, 75, 749-757.	3.4	8
2	Response to: "Hydroxychloroquine ineffective for COVID-19 prophylaxis in lupus and rheumatoid arthritis" by Singer et al. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e162-e162.	0.9	0
3	Response to: "Correspondence on "Festina lente": hydroxychloroquine, COVID-19 and the role of the rheumatologist" by Graef et al." by Lo et al. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e164-e164.	0.9	2
4	Response to: "Emergency arising from patients' fear of taking antimalarials during these COVID-19 times: are antimalarials as unsafe for cardiovascular health as recent reports suggest?" by Santos-Moreno et al. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e155-e155.	0.9	0
5	Response to SARS-CoV-2 vaccination in immune mediated inflammatory diseases: Systematic review and meta-analysis. <i>Autoimmunity Reviews</i> , 2022, 21, 102927.	5.8	132
6	SARS-CoV-2 Infection and COVID-19 Outcomes in Rheumatic Diseases: A Systematic Literature Review and Meta-Analysis. <i>Arthritis and Rheumatology</i> , 2022, 74, 766-775.	5.6	117
7	COVID-19 vaccine perceptions and uptake: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. <i>Lancet Rheumatology</i> , The, 2022, 4, e237-e240.	3.9	30
8	COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations. <i>Nature Reviews Rheumatology</i> , 2022, 18, 191-204.	8.0	105
9	Anxiety Symptoms Among Patients With Systemic Lupus Erythematosus Persist Over Time and Are Independent of SLE Disease Activity. <i>ACR Open Rheumatology</i> , 2022, 4, 432-440.	2.1	2
10	Baseline factors associated with self-reported disease flares following COVID-19 vaccination among adults with systemic rheumatic disease: results from the COVID-19 global rheumatology alliance vaccine survey. <i>Rheumatology</i> , 2022, 61, SI143-SI150.	1.9	40
11	Reactogenicity of the Messenger RNA SARS-CoV-2 Vaccines Associated With Immunogenicity in Patients With Autoimmune and Inflammatory Disease. <i>Arthritis Care and Research</i> , 2022, 74, 1953-1960.	3.4	5
12	Immunosuppression and SARS-CoV-2 breakthrough infections. <i>Lancet Rheumatology</i> , The, 2022, . .	3.9	10
13	Immunogenicity, breakthrough infection, and underlying disease flare after SARS-CoV-2 vaccination among individuals with systemic autoimmune rheumatic diseases. <i>Current Opinion in Pharmacology</i> , 2022, 65, 102243.	3.5	15
14	Belimumab for systemic lupus erythematosus " Focus on lupus nephritis. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 2072143.	3.3	6
15	Response to: "Antimalarial use and arrhythmias in COVID-19 and rheumatic patients: a matter of dose and inflammation?" by Erre et al. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e30-e30.	0.9	4
16	Response to: "Case series of acute arthritis in COVID-19 admission" by Lpez-Gonzlez et al. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e59-e59.	0.9	2
17	Antirheumatic Disease Therapies for the Treatment of COVID-19: A Systematic Review and Meta-Analysis. <i>Arthritis and Rheumatology</i> , 2021, 73, 36-47.	5.6	52
18	Reply to "Taking a stand against the politicization of medical research: how "swinging the pendulum" poses a hazard to clinical trials, study participants, and the progress of science". <i>Expert Review of Clinical Immunology</i> , 2021, 17, 105-107.	3.0	0

#	ARTICLE	IF	CITATIONS
19	Development of a digital toolkit to improve quality of life of patients with systemic lupus erythematosus. <i>Digital Health</i> , 2021, 7, 205520762110334.	1.8	6
20	Patient-Reported Outcomes in SLE. , 2021, , 213-227.		0
21	Hydroxychloroquine for the treatment of COVID-19 and its potential cardiovascular toxicity: Hero or villain?. <i>Best Practice and Research in Clinical Rheumatology</i> , 2021, 35, 101658.	3.3	5
22	The interplay between neutrophils, complement, and microthrombi in COVID-19. <i>Best Practice and Research in Clinical Rheumatology</i> , 2021, 35, 101661.	3.3	35
23	Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. <i>Nature Medicine</i> , 2021, 27, 717-726.	30.7	838
24	Addressing the challenges of the SARS-CoV-2 pandemic in patients affected by autoimmune and rheumatic disease. <i>Best Practice and Research in Clinical Rheumatology</i> , 2021, 35, 101664.	3.3	0
25	Cognitive dysfunction among people with systemic lupus erythematosus is associated with reduced participation in daily life. <i>Lupus</i> , 2021, 30, 1100-1107.	1.6	6
26	Increased complement activation is a distinctive feature of severe SARS-CoV-2 infection. <i>Science Immunology</i> , 2021, 6, .	11.9	153
27	Inflammatory arthritis in patients with COVID-19. <i>Translational Research</i> , 2021, 232, 49-59.	5.0	19
28	Systemic Lupus Erythematosus: The Next Generation of Ideas and Scientists. <i>Rheumatic Disease Clinics of North America</i> , 2021, 47, xv-xvi.	1.9	1
29	Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2. <i>Annals of Internal Medicine</i> , 2021, 174, 1572-1585.	3.9	273
30	B cells: more than just for antibodies in SARS-CoV-2 vaccine responses. <i>Lancet Rheumatology</i> , The, 2021, 3, e741-e743.	3.9	1
31	Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. <i>RMD Open</i> , 2021, 7, e001814.	3.8	121
32	Immediate effect of the COVID-19 pandemic on patient health, health-care use, and behaviours: results from an international survey of people with rheumatic diseases. <i>Lancet Rheumatology</i> , The, 2021, 3, e707-e714.	3.9	40
33	Exploring intentional medication non-adherence in patients with systemic lupus erythematosus: the role of physicianâ€‘patient interactions. <i>Rheumatology Advances in Practice</i> , 2021, 5, rkaa078.	0.7	9
34	Reduced antibody activity against SARS-CoV-2 B.1.617.2 delta virus in serum of mRNA-vaccinated individuals receiving tumor necrosis factor-Î± inhibitors. <i>Med</i> , 2021, 2, 1327-1341.e4.	4.4	31
35	Choroidal thickness in lupus nephritis. <i>Lupus</i> , 2020, 29, 205-209.	1.6	8
36	Use of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic: What Every Clinician Should Know. <i>Annals of Internal Medicine</i> , 2020, 172, 754-755.	3.9	176

#	ARTICLE	IF	CITATIONS
37	A Rush to Judgment? Rapid Reporting and Dissemination of Results and Its Consequences Regarding the Use of Hydroxychloroquine for COVID-19. <i>Annals of Internal Medicine</i> , 2020, 172, 819-821.	3.9	177
38	A Pharmacokinetics-Informed Approach to Navigating Hydroxychloroquine Shortages in Patients With Rheumatic Disease During the COVID-19 Pandemic. <i>ACR Open Rheumatology</i> , 2020, 2, 491-495.	2.1	4
39	The Patient Perspective on Using Digital Resources to Address Unmet Needs in Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2020, 73, 1568-1576.	3.4	12
40	Cognitive Domains Related to Participation among People with Systemic Lupus Erythematosus. <i>Archives of Physical Medicine and Rehabilitation</i> , 2020, 101, e100-e101.	0.9	0
41	The contribution of the observational research design to COVID-19 research. <i>Lancet Rheumatology</i> , 2020, 2, e650-e652.	3.9	1
42	Coronavirus disease 2019: investigational therapies in the prevention and treatment of hyperinflammation. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 1185-1204.	3.0	23
43	Measures of Sleep in Rheumatologic Diseases: Sleep Quality Patient-Reported Outcomes in Rheumatologic Diseases. <i>Arthritis Care and Research</i> , 2020, 72, 410-430.	3.4	3
44	Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1386-1388.	0.9	67
45	Swinging the pendulum: lessons learned from public discourse concerning hydroxychloroquine and COVID-19. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 659-666.	3.0	57
46	<i>Festina lente</i> : hydroxychloroquine, COVID-19 and the role of the rheumatologist. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 734-736.	0.9	35
47	The complement system in COVID-19: friend and foe?. <i>JCI Insight</i> , 2020, 5, .	5.0	295
48	The beneficial and pathogenic roles of complement in COVID-19. <i>Cleveland Clinic Journal of Medicine</i> , 2020, , .	1.3	5
49	Annals On Call - COVID-19: Is Chloroquine the Answer?. <i>Annals of Internal Medicine</i> , 2020, 172, OC1.	3.9	4
50	Not Having the Real Support That We Need: Patients' Experiences With Ambiguity of Systemic Lupus Erythematosus and Erosion of Social Support. <i>ACR Open Rheumatology</i> , 2019, 1, 135-144.	2.1	19
51	Reply. <i>Arthritis and Rheumatology</i> , 2019, 71, 1590-1592.	5.6	0
52	Development and Optimization of an ELISA to Quantitate C3(H2O) as a Marker of Human Disease. <i>Frontiers in Immunology</i> , 2019, 10, 703.	4.8	14
53	54...Blood concentrations of complement split product iC3b and serum C3 associate with systemic lupus erythematosus disease activity. , 2019, , .		0
54	Neutrophils promote VLA-4-dependent B cell antigen presentation and accumulation within the meninges during neuroinflammation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 24221-24230.	7.1	28

#	ARTICLE	IF	CITATIONS
55	Association of Blood Concentrations of Complement Split Product $C_3b$ and Serum C3 With Systemic Lupus Erythematosus Disease Activity. <i>Arthritis and Rheumatology</i> , 2019, 71, 420-430.	5.6	39
56	Barriers and Facilitators of Mentoring for Trainees and Early Career Investigators in Rheumatology Research: Current State, Identification of Needs, and Road Map to an Inter-Institutional Adult Rheumatology Mentoring Program. <i>Arthritis Care and Research</i> , 2018, 70, 445-453.	3.4	12
57	From mechanism to therapies in systemic lupus erythematosus. <i>Current Opinion in Rheumatology</i> , 2017, 29, 178-186.	4.3	32
58	B cell-derived IL-4 acts on podocytes to induce proteinuria and foot process effacement. <i>JCI Insight</i> , 2017, 2, .	5.0	48
59	New approaches in renal microscopy. <i>Current Opinion in Nephrology and Hypertension</i> , 2016, 25, 159-167.	2.0	7
60	Alveolar macrophage development in mice requires L-plastin for cellular localization in alveoli. <i>Blood</i> , 2016, 128, 2785-2796.	1.4	45
61	Barriers to and Facilitators of a Career as a Physician-Scientist Among Rheumatologists in the US. <i>Arthritis Care and Research</i> , 2015, 67, 1191-1201.	3.4	17
62	Brief Report: Chikungunya Viral Arthritis in the United States: A Mimic of Seronegative Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2015, 67, 1214-1220.	5.6	122
63	Immunological Mechanisms of Neuropsychiatric Lupus. <i>Current Immunology Reviews</i> , 2015, 11, 93-106.	1.2	1
64	Cardiac Manifestations of Systemic Lupus Erythematosus. <i>Rheumatic Disease Clinics of North America</i> , 2014, 40, 51-60.	1.9	128
65	Cell Depletion in Mice That Express Diphtheria Toxin Receptor under the Control of SiglecH Encompasses More Than Plasmacytoid Dendritic Cells. <i>Journal of Immunology</i> , 2014, 192, 4409-4416.	0.8	44
66	Novel Mechanism of Tumor Suppression by Polarity Gene <i>Discs Large 1</i> (DLG1) Revealed in a Murine Model of Pediatric B-ALL. <i>Cancer Immunology Research</i> , 2013, 1, 426-437.	3.4	23
67	Rac1 Activation in Podocytes Induces Rapid Foot Process Effacement and Proteinuria. <i>Molecular and Cellular Biology</i> , 2013, 33, 4755-4764.	2.3	107
68	Macrophages modulate cardiac function in lipotoxic cardiomyopathy. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2012, 303, H1366-H1373.	3.2	39
69	New roles revealed for T cells and DCs in glomerulonephritis. <i>Journal of Clinical Investigation</i> , 2009, 119, 1074-1076.	8.2	11
70	Complement C5a Receptor Is Essential for the Optimal Generation of Antiviral CD8+ T Cell Responses. <i>Journal of Immunology</i> , 2004, 173, 2524-2529.	0.8	97
71	IL-15 enhances survival and function of HIV-specific CD8+ T cells. <i>Blood</i> , 2003, 101, 1024-1029.	1.4	123
72	Preparation of 9,9-dimethoxytetracyclo[8.5.0.02,8.07,11]pentadeca-3,5,12,14,-tetraene and conversion to hexacyclo[8.5.1.14,7.05,14.06,12.011,15.016,17]heptadeca-2,8-diene-13-one using a domino Diels-Alder reaction. <i>Tetrahedron</i> , 1998, 54, 7013-7024.	1.9	10